Compare
Gossamer Bio, Inc. vs Lexicon Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc vs Septerna, Inc.
| Latest fiscal year | Gossamer Bio, Inc. GOSS | Lexicon Pharmaceuticals, Inc. LXRX | Protagonist Therapeutics, Inc PTGX | Septerna, Inc. SEPN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $48.47M | $49.80M | $46.02M | $45.95M |
| Revenue growth (YoY) | -57.7% | +60.2% | -89.4% | n/m |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -352.2% | -98.2% | -343.6% | -148.6% |
| Net margin | -351.5% | -101.1% | -282.8% | -106.4% |
| Net income | -$170.37M | -$50.34M | -$130.15M | -$48.88M |
| EPS (Diluted) | -$0.75 | -$0.14 | -$2.05 | -$1.10 |
| Operating cash flow | -$171.27M | -$67.85M | $57.67M | $110.19M |
| Free cash flow | -$171.34M | -$67.85M | $56.08M | $109.67M |
| Cash & equivalents | $37.73M | $34.33M | $128.39M | $120.72M |
| Total assets | $172.25M | $184.99M | $668.19M | $596.19M |
| Total liabilities | $295.01M | $77.45M | $53.48M | $214.26M |
| Shareholders' equity | -$122.76M | $107.54M | $614.71M | $381.93M |
| Return on year-end equity | n/a | -46.8% | -21.2% | -12.8% |
| Shares outstanding | 233.68M | 365.85M | 62.58M | 44.81M |
Revenue, most recent five fiscal years
| Fiscal year | Gossamer Bio, Inc. | Lexicon Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc | Septerna, Inc. |
|---|---|---|---|---|
| Latest | $48.47M Ended 2025-12-31 | $49.80M Ended 2025-12-31 | $46.02M Ended 2025-12-31 | $45.95M Ended 2025-12-31 |
| 1 year earlier | $114.70M Ended 2024-12-31 | $31.08M Ended 2024-12-31 | $434.43M Ended 2024-12-31 | $1.07M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $1.20M Ended 2023-12-31 | $60.00M Ended 2023-12-31 | $151.0K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $139.0K Ended 2022-12-31 | $26.58M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $298.0K Ended 2021-12-31 | $27.36M Ended 2021-12-31 | n/a |